Results 201 to 210 of about 249,854 (357)

Theory of Planned Behaviour Constructs as Predictors of Antiplatelet Medication Adherence Following Percutaneous Coronary Intervention: A Cross-Sectional Study in Saudi Arabia. [PDF]

Healthcare (Basel)
Aljuhani M, Almutairi AS, Alshehri WM, Alodhailah AM.   +3 more
europepmc   +1 more source

Hemocompatibility Outcomes After Aspirin Withdrawal in Long‐Term HeartMate 3 Left Ventricular Assist Device Patients on Vitamin K Antagonists

Artificial Organs, EarlyView.
Aspirin discontinuation in long‐term, stable Heart Mate 3 LVAD patients maintained on Vitamin K antagonists did not increase hemocompatibility‐related adverse events. These findings support the safety of simplified antithrombotic therapy and extend randomized evidence for aspirin avoidance to the long‐term management of Heart Mate 3 recipients ...
Melanie Arnreiter, Barbara Karner, Hebe Al Asadi, Christina Abd El‐Malak, Christiane Marko, Daniel Zimpfer, Julia Riebandt, Roxana Moayedifar, Thomas Schlöglhofer   +8 more
wiley   +1 more source

Intravenous thrombolysis versus antiplatelet standard care for patients with mild acute ischemic stroke: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Zhou Y, Zhou Y, Hunag G, Wang H.
europepmc   +1 more source

Percutaneous Intervention in External Outflow Graft Obstruction of Magnetically Levitated Left Ventricular Assist Device: Long‐Term Follow‐Up and Quality of Life

Artificial Organs, EarlyView.
eOGO is an uncommon adverse event in patients on long‐term LVAD support. Thirty‐one eOGO patients were identified in a single‐centre HM3 implantation program. Twenty patients underwent percutaneous stenting. This treatment resulted in immediate LVAD flow improvement and yielded satisfactory quality‐of‐life results, with 62.5% patients assigned a fair ...
Anna Huang, Julia Stein, Vanessa I. T. Zwaans, Carla L. Schuering, Gaik Nersesian, Christoph Hoermandinger, Markus Müller, Johanna Mulzer, Stephan Dreysse, Philipp Stawowy, Christoph T. Starck, Joerg Kempfert, Evgenij V. Potapov, Volkmar Falk, Leonhard Wert   +14 more
wiley   +1 more source

Antithrombotic Therapy in Percutaneous Atrial Structural Interventions. [PDF]

J Cardiovasc Dev Dis
Pitsikakis K, Skalidis I, Skalidis E, Lempidakis D, Papoutsakis A, Sideras E, Zacharis E, Petousis S, Hamilos M.   +8 more
europepmc   +1 more source

Identification of Coagulation Phenotypes Using Viscoelastic and Conventional Assays During Veno‐Venous Extracorporeal Membrane Oxygenation: A Hierarchical Clustering Analysis

Artificial Organs, EarlyView.
Hierarchical clustering of viscoelastic and conventional coagulation parameters identified three distinct phenotypes in V‐V ECMO patients, revealing substantial APTT–CK‐R discordance and highlighting the value of TEG‐derived markers for detecting coagulopathy not captured by standard monitoring.
Daisuke Irimada, Yudai Iwasaki, Yusuke Takei, Moe Oyama, Ami Tanaka, Shinichi Yamaguchi, Naoya Kobayashi, Daisuke Konno, Takuya Shiga, Masanori Yamauchi   +9 more
wiley   +1 more source

Antithrombotic management in magnetic resonance-guided focused ultrasound: Should these therapies be discontinued? [PDF]

Surg Neurol Int
Cabrera-Montes J, Cabrera JÁ.
europepmc   +1 more source

Device‐Induced Blood Damage in Pump‐Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps

Artificial Organs, EarlyView.
Shear‐induced blood damage—including hemolysis, platelet and neutrophil injury, and von Willebrand factor (vWF) degradation—was evaluated for the BrioVAD and HM3 using an in vitro circulatory loop under clinically relevant conditions. Across 15 biomarkers (n > 6 per group), no significant differences were observed between the two devices.
Wenji Sun, Kiersten P. Clark, Douglas Tran, John C. Vandenberge, Nancy Kim, Shigang Wang, Anik Tarafder, Randy Perez, Bartley P. Griffith, Dong Han   +9 more
wiley   +1 more source

Seguimiento de gestante con síndrome de plaquetas pegajosas: primer caso comunicado en Cuba

Revista Cubana de Hematología, Inmunología y Hemoterapia
El síndrome de plaquetas pegajosas es una entidad en la que se presentan hiperagregabilidad plaquetaria y manifestaciones clínicas trombóticas. Fue observada hace más de 30 años en personas jóvenes con eventos oclusivos, arteriales, venosos, miorcárdicos,
Dunia Castillo-González, Loreta Rodríguez-Pérez, Roberto Rodríguez-López, Aida García del Collado, Maribel Tejeda-González   +4 more
doaj  

Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

The Lancet, 2016
M. I. Baharoglu, C. Cordonnier, R. Salman, K. de Gans, M. Koopman, A. Brand, C. B. Majoie, L. Beenen, H. Marquering, M. Vermeulen, P. Nederkoorn, R. J. de Haan, Yvo B. W. E. M. Roos   +12 more
semanticscholar   +1 more source